

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 March 2004 (25.03.2004)

PCT

(10) International Publication Number
WO 2004/024165 A1

(51) International Patent Classification⁷: **A61K 31/66**,
31/405, A61P 35/00, A61K 45/06

[AU/AU]; 11 Albion Street, South Yarra, Victoria 3141 (AU).

(21) International Application Number:
PCT/EP2003/009972

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(22) International Filing Date:
8 September 2003 (08.09.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0220885.8 9 September 2002 (09.09.2002) GB

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(71) Applicant (*for all designated States except AT, US*): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(71) Applicant (*for AT only*): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BAULCH-BROWN, Cindy, Maree** [AU/AU]; 38 Teatree Drive, South Morang, Victoria 3752 (AU). **SPENCER, Andrew**

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINATION THERAPY COMPRISING A BISPHOSPHONATE AND A HMG-COA REDUCTASE INHIBITOR

(57) Abstract: A pharmaceutical composition for treatment of malignancies, in particular multiple myeloma (MM), comprises in combination a bisphosphonate, e.g. zoledronic acid or a salt or ester, and an HMG-CoA reductase inhibitor for simultaneous, sequential or separate use. Also provided is a method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonate and an effective amount of an HMG-CoA reductase inhibitor.



WO 2004/024165 A1

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/09972

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/66 A61K31/405 A61P35/00 A61K45/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE, WPI Data, PAJ, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BERKHOUT T A ET AL: "THE NOVEL CHOLESTEROL-LOWERING DRUG SR-12813 INHIBITS CHOLESTEROL SYNTHESIS VIA AN INCREASED DEGRADATION OF 3-HYDROXY-3- METHYLGLUTARYL-COENZYME A REDUCTASE" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 271, no. 24, 14 June 1996 (1996-06-14), pages 14376-14382, XP001026499 ISSN: 0021-9258 abstract; table 2 ---	1,6
X	WO 99 45923 A (FISHER JOHN E ;MERCK & CO INC (US); RODAN GIDEON A (US)) 16 September 1999 (1999-09-16) claims 16-19 --- -/-	1,6-9



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

16 January 2004

Date of mailing of the international search report

30/01/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Greif, G

INTERNATIONAL SEARCH REPORT

International Publication No

PCT/EP 03/09972

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2001/025028 A1 (FISHER JOHN E ET AL) 27 September 2001 (2001-09-27) claims 1-19 ----	1,6-9
X	US 2002/028826 A1 (CHEN BANG-CHI ET AL) 7 March 2002 (2002-03-07) abstract; claims 1,40 ----	10
Y		2-5,11, 12
X	US 2002/061901 A1 (CHEN BANG-CHI ET AL) 23 May 2002 (2002-05-23) abstract; claims 1,39,40 ----	10
Y		2-5,11, 12
X	WO 99 58505 A (WARNER LAMBERT CO ;LEOPOLD JUDITH (US); NEWTON ROGER SCHOFIELD (US) 18 November 1999 (1999-11-18) page 29, line 13-28 page 31, line 3-32; claims 1,22,23 ----	10,11
Y		2-5,12
X	GARRETT I R ET AL: "STATINS AND BONE FORMATION" CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, SCHIPHOL, NL, vol. 7, no. 8, 2001, pages 715-736, XP008016599 ISSN: 1381-6128 page 715, left-hand column, paragraph 1 p.719, right column, "Effect on tumor cells" ----	10-12
Y		2-5
X	GEBHARDT A ET AL: "EFFECTS OF PRAVASTATIN, A HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITOR, ON TWO HUMAN TUMOUR CELL LINES" JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER INTERNATIONAL, BERLIN, DE, vol. 121, no. 6, 1995, pages 343-349, XP009010214 ISSN: 0171-5216 abstract; figure 1; table 1 ----	10,11
Y		2-5,12
	--- -/--	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LEE S J ET AL: "Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells." THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 24 APR 1998, vol. 273, no. 17, 24 April 1998 (1998-04-24), pages 10618-10623, XP002267123 ISSN: 0021-9258 abstract	10,11
Y	page 10622, right-hand column, paragraph 2 ---	2-5,12
X	LARSSON O: "HMG-COA REDUCTASE INHIBITORS: ROLE IN NORMAL AND MALIGNANT CELLS" CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, vol. 3, no. 22, 1996, pages 197-212, XP001070345 ISSN: 1040-8428	10-12
Y	the whole document ---	2-5
X	WO 02 28270 A (SCHUMM BROOKE III ;KINDNESS GEORGE (US); PROBIOCHEM LLC (US); GUIL) 11 April 2002 (2002-04-11)	10,11
Y	abstract; claims 1,2 ---	2-5,12
Y	SANTINI D ET AL: "Pamidronate (P) induces modifications of circulating angiogenetic factors in cancer patients" EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 37, April 2001 (2001-04), pages S262-S263, XP004478214 ISSN: 0959-8049 abstract	2-5
Y	WITTERS L ET AL: "Inhibition of growth of human breast cancer cell lines with the combination of zoledronic acid and a COX-2 inhibitor" EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 37, April 2001 (2001-04), page S78 XP004477519 ISSN: 0959-8049 abstract --- -/--	2-5

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>PECHERSTORFER M ET AL: "A randomized study of ibandronate and pamidronate in hypercalcemia of malignancy (HCM). Ibandronate is more effective in the subset of patients with severe HCM and has at least equal efficacy to pamidronate in HCM patients with less elevated baseline calcium levels"</p> <p>EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 37, April 2001 (2001-04), page S171 XP004477864 ISSN: 0959-8049 abstract</p> <p>---</p>	2-5
Y	<p>OURA S ET AL: "Effective alendronate therapy against a bone metastasis occurring during docetaxel therapy for breast cancer--a case report"</p> <p>CANCERLIT, XP002232827 abstract</p> <p>---</p>	2-5
Y	<p>FREYER G ET AL: "Palliative hormone therapy, low dose chemotherapy and bisphosphonate in breast cancer patients with bone marrow involvement and pancytopenia; report of pilot experience"</p> <p>EUROPEAN JOURNAL OF INTERNAL MEDICINE, ELSEVIER, AMSTERDAM,, NL, vol. 11, 2000, pages 329-333, XP002257266 ISSN: 0953-6205 abstract</p> <p>---</p>	2-5
Y	<p>SHIPMAN C M ET AL: "BISPHOSPHONATES INDUCE APOPTOSIS IN HUMAN MYELOMA CELL LINES: A NOVEL ANTI-TUMOR ACTIVITY"</p> <p>BRITISH JOURNAL OF HAEMATOLOGY, OXFORD, GB, vol. 98, no. 3, September 1997 (1997-09), pages 665-672, XP008016800 ISSN: 0007-1048 abstract</p> <p>-----</p>	2-5

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/09972

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9945923	A	16-09-1999	AU 2901199 A	27-09-1999
			CA 2323448 A1	16-09-1999
			EP 1061917 A1	27-12-2000
			JP 2002506030 T	26-02-2002
			WO 9945923 A1	16-09-1999
			US 2001025028 A1	27-09-2001
US 2001025028	A1	27-09-2001	AU 2901199 A	27-09-1999
			CA 2323448 A1	16-09-1999
			EP 1061917 A1	27-12-2000
			JP 2002506030 T	26-02-2002
			WO 9945923 A1	16-09-1999
US 2002028826	A1	07-03-2002	US 2002061901 A1	23-05-2002
			AU 6686001 A	24-12-2001
			BR 0111571 A	01-07-2003
			CA 2412979 A1	20-12-2001
			CN 1436174 T	13-08-2003
			CZ 20023931 A3	12-03-2003
			EP 1294696 A2	26-03-2003
			HU 0302955 A2	29-12-2003
			NO 20026011 A	12-02-2003
			WO 0196311 A2	20-12-2001
US 2002061901	A1	23-05-2002	US 2002028826 A1	07-03-2002
			AU 6686001 A	24-12-2001
			BR 0111571 A	01-07-2003
			CA 2412979 A1	20-12-2001
			CN 1436174 T	13-08-2003
			CZ 20023931 A3	12-03-2003
			EP 1294696 A2	26-03-2003
			HU 0302955 A2	29-12-2003
			NO 20026011 A	12-02-2003
			WO 0196311 A2	20-12-2001
WO 9958505	A	18-11-1999	AU 758891 B2	03-04-2003
			AU 3979299 A	29-11-1999
			BG 105003 A	31-07-2001
			BR 9911785 A	03-04-2001
			CA 2331295 A1	18-11-1999
			CN 1306515 T	01-08-2001
			EE 200000660 A	15-04-2002
			EP 1077949 A2	28-02-2001
			HR 20000771 A1	30-06-2001
			HU 0102322 A2	28-11-2001
			JP 2002514628 T	21-05-2002
			NO 20005680 A	10-01-2001
			NZ 508357 A	27-09-2002
			PL 344662 A1	19-11-2001
			SK 16742000 A3	10-07-2001
			WO 9958505 A2	18-11-1999
			US 6492410 B1	10-12-2002
			ZA 200006491 A	09-05-2002
WO 0228270	A	11-04-2002	US 2002086894 A1	04-07-2002
			AU 1305002 A	15-04-2002
			WO 0228270 A2	11-04-2002
			WO 02094021 A1	28-11-2002

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/09972

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0228270	A	WO 02083124 A1	24-10-2002
		WO 02067853 A2	06-09-2002
		US 2003162829 A1	28-08-2003
		US 2002132781 A1	19-09-2002
		US 2002169195 A1	14-11-2002
		WO 03022268 A1	20-03-2003
<hr/>			